Clemens O Hanemann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3329807/publications.pdf

Version: 2024-02-01

144 papers	7,033 citations	53794 45 h-index	71685 76 g-index
155 all docs	155 docs citations	155 times ranked	7260 citing authors

#	Article	IF	Citations
1	The peripheral myelin protein gene PMPâ€“22 is contained within the Charcotâ€“Marieâ€“Tooth disease type 1A duplication. Nature Genetics, 1992, 1, 171-175.	21.4	404
2	Peripheral myelin proteinâ€“22 gene maps in the duplication in chromosome 17p11.2 associated with Charcotâ€“Marieâ€“Tooth 1A. Nature Genetics, 1992, 1, 176-179.	21.4	325
3	Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus. Cell, 2010, 140, 477-490.	28.9	287
4	X-linked Bulbospinal Neuronopathy. Archives of Neurology, 2002, 59, 1921.	4.5	206
5	Merlin/NF2 Loss-Driven Tumorigenesis Linked to CRL4DCAF1-Mediated Inhibition of the Hippo Pathway Kinases Lats1 and 2 in the Nucleus. Cancer Cell, 2014, 26, 48-60.	16.8	198
6	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, 2019, 21, 901-910.	1.2	184
7	Heterozygous R1101K mutation of theDCTN1 gene in a family with ALS and FTD. Annals of Neurology, 2005, 58, 777-780.	5.3	182
8	Schwannomas and Their Pathogenesis. Brain Pathology, 2014, 24, 205-220.	4.1	151
9	Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain, 2002, 125, 996-1004.	7.6	122
10	Accumulation of autophagosomes confers cytotoxicity. Journal of Biological Chemistry, 2017, 292, 13599-13614.	3.4	122
11	Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2013, 12, 339-345.	10.2	118
12	Dissecting and Targeting the Growth Factorâ€“Dependent and Growth Factorâ€“Independent Extracellular Signal-Regulated Kinase Pathway in Human Schwannoma. Cancer Research, 2008, 68, 5236-5245.	0.9	115
13	Transient, Recurrent, White Matter Lesions in X-linked Charcot-Marie-Tooth Disease With Novel Connexin 32 Mutation. Archives of Neurology, 2003, 60, 605.	4.5	111
14	Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Human Molecular Genetics, 2003, 12, 1211-1221.	2.9	107
15	Advances in multidisciplinary therapy for meningiomas. Neuro-Oncology, 2019, 21, i18-i31.	1.2	102
16	Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. American Journal of Medical Genetics, Part A, 2012, 158A, 24-41.	1.2	101
17	Imaging and diagnostic advances for intracranial meningiomas. Neuro-Oncology, 2019, 21, i44-i61.	1.2	100
18	Molecular and translational advances in meningiomas. Neuro-Oncology, 2019, 21, i4-i17.	1.2	92

#	Article	IF	Citations
19	Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Therapy, 2003, 10, 84-94.	4.5	91
20	A Clue to the Therapy of Neurofibromatosis Type 2. Cancer Journal (Sudbury, Mass), 2004, 10, 20-25.	2.0	91
21	Congenital axonal neuropathy caused by deletions in the spinal muscular atrophy region. Annals of Neurology, 1997, 42, 364-368.	5.3	87
22	Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurology, The, 2015, 14, 883-892.	10.2	85
23	Î”⁹â€tetrahydrocannabinol (Î”⁹â€THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. Neuropathology and Applied Neurobiology, 2012, 38, 535-547.	3.2	84
24	Merlin-Deficient Human Tumors Show Loss of Contact Inhibition and Activation of Wnt/Î²-Catenin Signaling Linked to the PDGFR/Src and Rac/PAK Pathways. Neoplasia, 2011, 13, 1101-IN2.	5.3	83
25	FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patients. Journal of Medical Genetics, 2004, 41, e50-e50.	3.2	82
26	ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro-Oncology, 2010, 12, 834-843.	1.2	81
27	Magic but treatable? Tumours due to loss of Merlin. Brain, 2008, 131, 606-615.	7.6	80
28	Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. Journal of Medical Genetics, 2015, 52, 699-705.	3.2	78
29	Peripheral myelin protein-22 expression in charcot-marie-tooth disease type 1a sural nerve biopsies. Journal of Neuroscience Research, 1994, 37, 654-659.	2.9	72
30	Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nature Reviews Neurology, 2011, 7, 392-399.	10.1	71
31	Axl/Gas6/NFÎºB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene, 2014, 33, 336-346.	5.9	71
32	Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Human Molecular Genetics, 2002, 11, 69-76.	2.9	66
33	Pathogenesis of Charcotâ€“Marieâ€“Tooth 1A (CMT1A) neuropathy. Trends in Neurosciences, 1998, 21, 282-286.	8.6	63
34	Isolation and Characterization of Schwann Cells from Neurofibromatosis Type 2 Patients. Neurobiology of Disease, 1998, 5, 55-64.	4.4	62
35	Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genetics in Medicine, 2022, 24, 1967-1977.	2.4	60
36	Achieving consensus for clinical trials. Neurology, 2013, 81, S1-5.	1.1	59

#	Article	IF	Citations
37	The Tumor Suppressor Merlin Controls Growth in Its Open State, and Phosphorylation Converts It to a Less-Active More-Closed State. Developmental Cell, 2012, 22, 703-705.	7.0	56
38	Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. Neuro-Oncology, 2019, 21, i32-i43.	1.2	56
39	Merlin, a multiâ€suppressor from cell membrane to the nucleus. FEBS Letters, 2012, 586, 1403-1408.	2.8	54
40	Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism. EBioMedicine, 2019, 40, 77-91.	6.1	54
41	Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs. Acta Neuropathologica, 1997, 94, 310-315.	7.7	51
42	Merlin isoform 2 in neurofibromatosis type 2â€“associated polyneuropathy. Nature Neuroscience, 2013, 16, 426-433.	14.8	51
43	News on the genetics, epidemiology, medical care and translational research of Schwannomas. Journal of Neurology, 2006, 253, 1533-1541.	3.6	49
44	Artesunate induces necrotic cell death in schwannoma cells. Cell Death and Disease, 2014, 5, e1466-e1466.	6.3	49
45	An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures. Scientific Reports, 2018, 8, 13537.	3.3	49
46	Improved culture methods to expand schwann cells with altered growth behaviour from CMT1A patients. , 1998, 23, 89-98.		48
47	Long-term culture and characterization of human neurofibroma-derived Schwann cells. Journal of Neuroscience Research, 2000, 61, 524-532.	2.9	46
48	Mutation-dependent alteration in cellular distribution of peripheral myelin protein 22 in nerve biopsies from Charcotâ€“Marieâ€“Tooth type 1A. Brain, 2000, 123, 1001-1006.	7.6	46
49	Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro-Oncology, 2011, 13, 759-766.	1.2	46
50	Laryngospasm: An underdiagnosed symptom of X-linked spinobulbar muscular atrophy. Neurology, 2005, 64, 753-754.	1.1	45
51	Merlin/NF2 Functions Upstream of the Nuclear E3 Ubiquitin Ligase CRL4 ^{DCAF1} to Suppress Oncogenic Gene ExpressionA presentation from the 50th Annual Meeting of the American Society for Cell Biology in Philadelphia, Pennsylvania, 11 to 15 December 2010.. Science Signaling, 2011, 4, pt6.	3.6	45
52	Low affinity NGF receptor expression in CMT1 A nerve biopsies of different disease stages. Brain, 1996, 119, 1461-1469.	7.6	43
53	Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival. Oncogene, 2012, 31, 1710-1722.	5.9	42
54	Spinal Neurofibromatosis without CafÃ©-au-Lait Macules in Two Families with Null Mutations of the NF1 Gene. American Journal of Human Genetics, 2001, 69, 1395-1400.	6.2	41

#	Article	IF	Citations
55	Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis. Oncotarget, 2016, 7, 46603-46614.	1.8	41
56	Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. Journal of Neurology, 2014, 261, 963-969.	3.6	39
57	HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis. Journal of Clinical Investigation, 2020, 130, 3848-3864.	8.2	38
58	Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology, 2009, 55, 744-749.	2.9	37
59	Cannabinoid Receptor and Nâ€acyl Phosphatidylethanolamine Phospholipase Dâ€”Evidence for Altered Expression in Multiple Sclerosis. Brain Pathology, 2011, 21, 544-557.	4.1	37
60	Differential gene expression between human schwannoma and control Schwann cells. Neuropathology and Applied Neurobiology, 2006, 32, 605-614.	3.2	36
61	Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells. Brain, 2013, 136, 549-563.	7.6	35
62	PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Experimental Neurology, 2009, 218, 137-144.	4.1	34
63	Axon damage in CMT due to mutation in myelin protein P0. Neuromuscular Disorders, 2001, 11, 753-756.	0.6	32
64	Pathological Adhesion of Primary Human Schwannoma Cells is Dependent on Altered Expression of Integrins. Brain Pathology, 2003, 13, 352-363.	4.1	32
65	Expression of decorin mRNA in the nervous system of rat.. Journal of Histochemistry and Cytochemistry, 1993, 41, 1383-1391.	2.5	31
66	Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228. Cancer Biology and Therapy, 2005, 4, 385-387.	3.4	31
67	Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Lossâ€“Driven Tumorigenesis. Molecular Cancer Therapeutics, 2017, 16, 1693-1704.	4.1	31
68	Impaired intercellular adhesion and immature adherens junctions in merlinâ€deficient human primary schwannoma cells. Glia, 2008, 56, 506-515.	4.9	30
69	Balo's concentric sclerosis followed by MRI and positron emission tomography. Neuroradiology, 1993, 35, 578-580.	2.2	29
70	Actin-Rich Protrusions and Nonlocalized GTPase Activation in Merlin-Deficient Schwannomas. Journal of Neuropathology and Experimental Neurology, 2007, 66, 608-616.	1.7	29
71	Reduced Apoptosis Rates in Human Schwannomas. Brain Pathology, 2005, 15, 17-22.	4.1	28
72	Management of sialorrhoea in motor neuron disease: A survey of current UK practice. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 521-527.	1.7	28

#	Article	IF	Citations
73	Activation of multiple growth factor signalling pathways is frequent in meningiomas. Neuropathology, 2016, 36, 250-261.	1.2	28
74	MR-Pathologic Comparison of the Upper Spinal Cord in Different Motor Neuron Diseases. European Neurology, 2005, 53, 74-77.	1.4	27
75	A functional association between merlin and HEI10, a cell cycle regulator. Oncogene, 2006, 25, 4389-4398.	5.9	27
76	Altered Adhesive Structures and Their Relation to RhoGTPase Activation in Merlinâ€Deficient Schwannoma. Brain Pathology, 2009, 19, 27-38.	4.1	27
77	The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 317-327.	1.7	27
78	Cellular contaminants of adeno-associated virus vector stocks can enhance transduction. Gene Therapy, 1999, 6, 1045-1053.	4.5	26
79	A novel nonsense mutation in the ABC1 gene causes a severe syringomyelia-like phenotype of Tangier disease. Brain, 2003, 126, 920-927.	7.6	26
80	Changes in iron-regulatory gene expression occur in human cell culture models of Parkinsonâ€™s disease. Neurochemistry International, 2011, 59, 73-80.	3.8	26
81	High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells. Journal of Neuroscience Research, 2008, 86, 3212-3220.	2.9	25
82	Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? A national study reconciling previous conflicting literature. Journal of Neurology, 2020, 267, 607-615.	3.6	25
83	Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244. Neurobiology of Disease, 2010, 37, 141-146.	4.4	24
84	Cellular prion protein (PrPC) in the development of Merlin-deficient tumours. Oncogene, 2017, 36, 6132-6142.	5.9	24
85	Conclusions and future directions for the REiNS International Collaboration. Neurology, 2013, 81, S41-4.	1.1	23
86	Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology, 2016, 87, S40-8.	1.1	23
87	Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. EBioMedicine, 2017, 16, 76-86.	6.1	22
88	Secondary axon atrophy and neurological dysfunction in demyelinating neuropathies. Current Opinion in Neurology, 2002, 15, 611-615.	3.6	21
89	The role of insulinâ€like growth factors signaling in merlinâ€deficient human schwannomas. Glia, 2012, 60, 1721-1733.	4.9	21
90	Progression of hearing loss in neurofibromatosis type 2 according to genetic severity. Laryngoscope, 2019, 129, 974-980.	2.0	21

#	Article	IF	Citations
91	A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 1-9.	1.7	20
92	Voltage-dependent membrane currents of cultured human neurofibromatosis type 2 Schwann cells. , 1998, 24, 313-322.		19
93	Role of NF2 Haploinsufficiency in NF2â€associated Polyneuropathy. Brain Pathology, 2007, 17, 371-376.	4.1	19
94	Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use. Neurology, 2021, 97, S91-S98.	1.1	19
95	Quinidine impairs proliferation of neurofibromatosis type 2â€deficient human malignant mesothelioma cells. Cancer, 2003, 97, 1955-1962.	4.1	18
96	Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity. Clinical Genetics, 2019, 96, 151-162.	2.0	18
97	The p53/mouse double minute 2 homolog complex deregulation in merlinâ€deficient tumours. Molecular Oncology, 2015, 9, 236-248.	4.6	17
98	An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis. Cancer Research, 2017, 77, 5026-5038.	0.9	17
99	GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma. EBioMedicine, 2020, 59, 102941.	6.1	17
100	Enhanced Proliferation and Potassium Conductance of Schwann Cells Isolated from NF2 Schwannomas Can Be Reduced by Quinidine. Neurobiology of Disease, 2000, 7, 483-491.	4.4	16
101	Rearrangements of the intermediate filament GFAP in primary human schwannoma cells. Neurobiology of Disease, 2005, 19, 1-9.	4.4	16
102	Major histocompatibility complex class II expression and macrophage responses in genetically proven Charcot-Marie-Tooth type 1 and hereditary neuropathy with liability to pressure palsies. , 1998, 21, 1419-1427.		15
103	Medulloblastoma in a patient with the PTPN11 p.Thr468Met mutation. American Journal of Medical Genetics, Part A, 2013, 161, 2027-2029.	1.2	15
104	Lack of immune responses to immediate or delayed implanted allogeneic and xenogeneic Schwann cell suspensions. Glia, 1997, 21, 299-314.	4.9	14
105	Complicated hereditary spastic paraplegia with thin corpus callosum: Variation of phenotypic expression over time. Journal of Neurology, 2004, 251, 1285-1287.	3.6	13
106	Fludeoxyglucose F 18 Positron Emission Tomography and Computed Tomography of a Giant Retroperitoneal Schwannoma Occurring in a Patient With Neurofibromatosis Type 2. Archives of Neurology, 2005, 62, 674.	4.5	13
107	Sensitive Detection of Deletions of One or More Exons in the Neurofibromatosis Type 2 (NF2) Gene by Multiplexed Gene Dosage Polymerase Chain Reaction. Journal of Molecular Diagnostics, 2005, 7, 97-104.	2.8	13
108	Neurofibromatosis type 1 with involvement of the enteric nerves. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1163-1164.	1.9	13

#	Article	IF	Citations
109	Expression of câ€<scp>J</scp>un and <scp>S</scp>oxâ€2 in human schwannomas and traumatic neuromas. Histopathology, 2013, 62, 651-656.	2.9	13
110	The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors. Oncogene, 2016, 35, 3443-3453.	5.9	13
111	DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis â€“ a randomised controlled trial. Health Technology Assessment, 2016, 20, 1-186.	2.8	13
112	Hereditary motor neuropathies and motor neuron diseases: which is which. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, 186-189.	1.2	12
113	Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas. International Journal of Molecular Sciences, 2021, 22, 560.	4.1	12
114	The epidemiology of motor neurone disease in two counties in the southwest of England. Journal of Neurology, 2010, 257, 977-981.	3.6	11
115	Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. Cancer Research, 2022, 82, 235-247.	0.9	11
116	A Rapid Robust Method for Subgrouping Non-NF2 Meningiomas According to Genotype and Detection of Lower Levels of M2 Macrophages in AKT1 E17K Mutated Tumours. International Journal of Molecular Sciences, 2020, 21, 1273.	4.1	10
117	Constitutive activation of the EGFRâ€“STAT1 axis increases proliferation of meningioma tumor cells. Neuro-Oncology Advances, 2020, 2, vdaa008.	0.7	9
118	Hereditary demyelinating neuropathies: from gene to disease. Neurogenetics, 2001, 3, 53-57.	1.4	8
119	Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma. Cancers, 2020, 12, 3270.	3.7	8
120	Acquired rippling muscle disease in association with myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 125-126.	1.9	7
121	Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis. Acta Neurologica Scandinavica, 2018, 138, 47-54.	2.1	7
122	Biomarkers for differentiating grade II meningiomas from grade I: a systematic review. British Journal of Neurosurgery, 2021, 35, 696-702.	0.8	7
123	PMP22 expression in CMT1A neuropathy. Annals of Neurology, 1995, 37, 136-136.	5.3	6
124	Acquired neuromyotonia following upper respiratory tract infection: a case report. Cases Journal, 2009, 2, 7952.	0.4	6
125	Measuring quality of life in ALS/MND: validation of the WHOQOL-BREF. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 364-372.	1.7	5
126	Motor protein diseases of the nervous system. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 197-201.	2.1	4

#	Article	IF	Citations
127	Utilization of volumetric magnetic resonance imaging for baseline and surveillance imaging in Neuro-oncology. British Journal of Radiology, 2019, 92, 20190059.	2.2	4
128	Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1184-1187.	1.9	4
129	Unilateral cerebral hemisphere oedema as a peri-ictal phenomenon. Journal of Neurology, 2010, 257, 2094-2096.	3.6	3
130	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.7	3
131	The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications. Journal of the Neurological Sciences, 2022, 436, 120188.	0.6	3
132	Muscle injury in Guillain-BarrÃ© syndrome: a case report. Journal of Neurology, 1999, 246, 1207-1208.	3.6	2
133	Erratum to â€œAxon damage in CMT due to mutation in myelin protein P0â€•[Neuromusc. Disord. 11 (2001) 753â€“756]. Neuromuscular Disorders, 2002, 12, 432.	0.6	1
134	Kennedy Disease: Insights and Questionsâ€”Reply. Archives of Neurology, 2004, 61, 603.	4.5	1
135	Î”9â€“TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPARÎ³ DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.58-e2.	1.9	1
136	A Systematic Approach to Review of in vitro Methods in Brain Tumour Research (SAToRI-BTR): Development of a Preliminary Checklist for Evaluating Quality and Human Relevance. Frontiers in Bioengineering and Biotechnology, 2020, 8, 936.	4.1	1
137	Enhanced Proliferation and Potassium Conductance of Schwann Cells Isolated from NF2 Schwannomas Can Be Reduced by Quinidine. Neurobiology of Disease, 2001, 8, 181.	4.4	0
138	CLINICAL MORVAN'S AND ELECTRICAL MND. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.96-e4.	1.9	0
139	CSIG-02. TARGETING CONSTITUTIVE ACTIVATION OF THE EGFR-STAT1 AXIS DECREASES PROLIFERATION OF MENINGIOMA TUMOUR CELLS. Neuro-Oncology, 2019, 21, vi44-vi44.	1.2	0
140	The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma. Cancers, 2020, 12, 1744.	3.7	0
141	Abstract C164: Targeting receptor tyrosine kinases and their downstream signaling pathways in human schwannoma. , 2009, , .		0
142	Abstract 2609: The role of focal adhesion kinase (FAK), PI3K/AKT and p53/mouse double minute 2 homologue (MDM2) complex in the pathobiology of Merlin-deficient tumors. , 2014, , .		0
143	Abstract 704: Scaffold protein KSR1 is negatively regulated by merlin and promotes tumor development in merlin deficient tumors. , 2015, , .		0
144	Longâ€term culture and characterization of human neurofibromaâ€derived Schwann cells. Journal of Neuroscience Research, 2000, 61, 524-532.	2.9	0